IDXX Idexx Laboratories Inc stock chart & analysis
Conviction 20HealthcareScan · Fri, Nov 6, 2026Idexx Laboratories Inc (IDXX) closed at $676.04 (+0.79%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 71, RS Rating 71, -12.2% from its 52-week high, -0.1% year to date. Sector: Healthcare · In Vitro & in Vivo Diagnostic Substances.
Financials as of Wed, Sep 30, 2026 · quarterly.
IDXX technical analysis
Trend
IDXX's moving averages are mixed — no clean uptrend or downtrend. It closed 23.6% above the 50-day ($546.75) and 18.1% above the 200-day ($572.06). ADX(14) at 33 points to a strong, established trend. It meets 5 of 8 trend-template criteria.
Momentum
RSI(14) is 71, in overbought territory. The MACD histogram is positive. Its RS Rating of 71 puts its weighted 12-month performance ahead of about 71% of the US market, and its RS line is at a new high.
Volume and volatility
Volume on the latest session ran 0.9× its 20-day average. It trades about $434.6M a day on average. ATR(14) is $25.54, 3.8% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (0.25) shows accumulation.
Key levels
The chart pattern's support is $503.39 and its resistance $642.75. The 52-week range is $500.61 to $769.98; price is 12.2% below the high and 35.0% above the low. The VWAP anchored at the 52-week high is $592.28, below price.
Performance
IDXX returned +22.6% (1 week), +31.7% (1 month), +13.5% (3 months), +20.7% (6 months), -6.2% (1 year), -0.1% (year to date).
About Idexx Laboratories Inc
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
In Vitro & in Vivo Diagnostic Substances · Listed 1991 · 11,000 employees
Congress activity
Disclosed STOCK Act trades in IDXX · 10 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 April McClain Delaney house · D · MD · traded 2026-01-13 | Sell | $1K–$15K | 2026-01-13 | 2026-02-02 | |
 Byron Donalds house · R · FL · traded 2025-09-04 | Buy | $1K–$15K | 2025-09-04 | 2025-10-07 | |
April McClain Delaney house · D · MD · traded 2025-08-07 | Sell | $1K–$15K | 2025-08-07 | 2025-09-02 | |
April McClain Delaney house · D · MD · traded 2025-07-09 | Sell | $1K–$15K | 2025-07-09 | 2025-08-05 | |
 Jefferson Shreve house · R · IN · traded 2025-05-12 | Sell | $100K–$250K | 2025-05-12 | 2025-06-22 | |
 Rob Bresnahan house · PA · traded 2025-05-15 | Buy | $1K–$15K | 2025-05-15 | 2025-06-09 | |
Jefferson Shreve house · R · IN · traded 2025-04-07 | Buy | $50K–$100K | 2025-04-07 | 2025-05-08 | |
April McClain Delaney house · D · MD · traded 2025-04-09 | Buy | $1K–$15K | 2025-04-09 | 2025-05-02 | |
April McClain Delaney house · D · MD · traded 2025-04-04 | Buy | $1K–$15K | 2025-04-04 | 2025-05-02 | |
April McClain Delaney house · D · MD · traded 2025-04-07 | Buy | $1K–$15K | 2025-04-07 | 2025-05-02 |
Insider activity
SEC Form 4 transactions in IDXX · open-market 9 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
JUNIUS DANIEL M Director · Common Stock · 2026-11-04 | Sell | 700 | $494K | 2026-11-04 | 2026-11-05 |
JUNIUS DANIEL M Director · Common Stock · 2026-11-04 | Sell | 500 | $351K | 2026-11-04 | 2026-11-05 |
Lane Michael Executive Vice President · Common Stock · 2026-11-04 | Sell | 242.944 | $167K | 2026-11-04 | 2026-11-05 |
Lane Michael Executive Vice President · Common Stock · 2026-11-04 | Sell | 2.06K | $1.4M | 2026-11-04 | 2026-11-05 |
Lane Michael Executive Vice President · Common Stock · 2026-11-04 | Sell | 1.68K | $1.2M | 2026-11-04 | 2026-11-05 |
MAZELSKY JONATHAN JAY Executive Chair of the Board · Common Stock · 2026-11-04 | Exercise | 25.14K | $4.5M | 2026-11-04 | 2026-11-05 |
MAZELSKY JONATHAN JAY Executive Chair of the Board · Common Stock · 2026-11-04 | Sell | 1.95K | $1.4M | 2026-11-04 | 2026-11-05 |
MAZELSKY JONATHAN JAY Executive Chair of the Board · Common Stock · 2026-11-04 | Sell | 4.08K | $2.8M | 2026-11-04 | 2026-11-05 |
MAZELSKY JONATHAN JAY Executive Chair of the Board · Common Stock · 2026-11-04 | Sell | 1.67K | $1.2M | 2026-11-04 | 2026-11-05 |
MAZELSKY JONATHAN JAY Executive Chair of the Board · Common Stock · 2026-11-04 | Sell | 4.54K | $3.2M | 2026-11-04 | 2026-11-05 |
SEC filings
EDGAR filings in IDXX · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.